Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E L Sievers

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Expert Opinion on Biological Therapy|December 1, 2001
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapseE L Sievers
Current Opinion in Oncology|February 25, 2000
Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugatesE L Sievers
Cancer Chemotherapy and Pharmacology|August 19, 2000
Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugatesE L Sievers
Current Opinion in Oncology|October 24, 2001
Mylotarg: antibody-targeted chemotherapy comes of ageE L Sievers, M Linenberger
Hematology/Oncology Clinics of North America|October 26, 2001
Targeted therapies for high-risk acute myeloid leukemiaJ P Perentesis, E L Sievers
Blood Reviews|June 1, 1996
Non-malignant neutropeniaE L Sievers, D C Dale
Journal of Pediatric Hematology/Oncology|May 1, 1995
Detection of minimal residual disease in acute myelogenous leukemiaE L Sievers, M R Loken
Current Opinion in Hematology|July 6, 2000
Detection of minimal residual disease in acute leukemiaE L Sievers, J P Radich
Medical and Pediatric Oncology|April 1, 1996
Long-term survival of a patient with primary sellar choriocarcinoma with pulmonary metastases: a case reportE L Sievers, M Berger, J R Geyer
Cancer Biotherapy & Radiopharmaceuticals|January 13, 2001
Cell surface receptor-targeted therapy of acute myeloid leukemia: a reviewA E Frankel, E L Sievers, D A Scheinberg
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Expert Opinion on Biological Therapy|December 1, 2001
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapseE L Sievers
Current Opinion in Oncology|February 25, 2000
Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugatesE L Sievers
Cancer Chemotherapy and Pharmacology|August 19, 2000
Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugatesE L Sievers
Current Opinion in Oncology|October 24, 2001
Mylotarg: antibody-targeted chemotherapy comes of ageE L Sievers, M Linenberger
Hematology/Oncology Clinics of North America|October 26, 2001
Targeted therapies for high-risk acute myeloid leukemiaJ P Perentesis, E L Sievers
Blood Reviews|June 1, 1996
Non-malignant neutropeniaE L Sievers, D C Dale
Journal of Pediatric Hematology/Oncology|May 1, 1995
Detection of minimal residual disease in acute myelogenous leukemiaE L Sievers, M R Loken
Current Opinion in Hematology|July 6, 2000
Detection of minimal residual disease in acute leukemiaE L Sievers, J P Radich
Medical and Pediatric Oncology|April 1, 1996
Long-term survival of a patient with primary sellar choriocarcinoma with pulmonary metastases: a case reportE L Sievers, M Berger, J R Geyer
Cancer Biotherapy & Radiopharmaceuticals|January 13, 2001
Cell surface receptor-targeted therapy of acute myeloid leukemia: a reviewA E Frankel, E L Sievers, D A Scheinberg
Pageof 3